Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients

Zeng, Mingyue; Ding, Siruiyun; Zhang, Hui; Huang, Qianqian; Ren, Yi; Guo, Pengxiang

doi:10.1002/jcla.23151

Cited by 8 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ITGA7 also has been suggested to be a biomarker for AML patients as ITGA7 expression in AML patients was significantly increased compared to the control and correlated with a poorer prognosis. Patients with either high ITGA7 mRNA or protein expression had a shorter event-free survival (EFS) and overall survival (OS) compared to low ITAG7 patients (198).…”

Section: Integrin a 7 (Itga7)mentioning

confidence: 99%

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia

et al. 2020

View full text Add to dashboard Cite

The interaction between leukemia cells and the bone microenvironment is known to provide drug resistance in leukemia cells. This phenomenon, called cell adhesion-mediated drug resistance (CAM-DR), has been demonstrated in many subsets of leukemia including B- and T-acute lymphoblastic leukemia (B- and T-ALL) and acute myeloid leukemia (AML). Cell adhesion molecules (CAMs) are surface molecules that allow cell–cell or cell–extracellular matrix (ECM) adhesion. CAMs not only recognize ligands for binding but also initiate the intracellular signaling pathways that are associated with cell proliferation, survival, and drug resistance upon binding to their ligands. Cadherins, selectins, and integrins are well-known cell adhesion molecules that allow binding to neighboring cells, ECM proteins, and soluble factors. The expression of cadherin, selectin, and integrin correlates with the increased drug resistance of leukemia cells. This paper will review the role of cadherins, selectins, and integrins in CAM-DR and the results of clinical trials targeting these molecules.

show abstract

Section: Integrin a 7 (Itga7)mentioning

confidence: 99%

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[5][6][7][8] There is thus a clear need to identify prognostic biomarkers capable of stratifying AML patients based on their risk level to guide more appropriate treatment and clinical management efforts. 9,10 Circular RNAs (circRNAs) exhibit a covalently closed looplike morphology and lack coding potential, 5′ caps, and 3′ polyadenylated tails. 11,12 These circRNAs can regulate the immune response, oncogenic progression, and chemoresistance among other processes.…”

Section: Introductionmentioning

confidence: 99%

“… 5 , 6 , 7 , 8 There is thus a clear need to identify prognostic biomarkers capable of stratifying AML patients based on their risk level to guide more appropriate treatment and clinical management efforts. 9 , 10 …”

Section: Introductionmentioning

confidence: 99%

Serum hsa_circ_0079480 is a novel prognostic marker for acute myeloid leukemia

Guo

Kou

Song

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background The dysregulated expression of serum circular RNAs (circRNAs) has previously been linked to the prognosis of acute myeloid leukemia (AML) patients, but the clinical and prognostic relevance of serum hsa_circ_0079480 levels in this oncogenic setting have yet to be established. Herein, we assessed the putative prognostic relevance of circulating hsa_circ_0079480 levels in AML patient serum. Methods Serum was prepared from blood samples collected from 236 AML patients and 160 healthy controls, with hsa_circ_0079480 levels therein being quantified by quantitative real‐time reverse transcription‐polymerase chain reaction (qRT‐PCR) after which the clinical value of these levels was assessed. Results Acute myeloid leukemia patients were found to exhibit significant hsa_circ_0079480 upregulation in their serum as compared to serum from healthy controls, with such upregulation being most profound in individuals with M4/M5 type disease and to be more common in patients with poor cytogenic risk or high white blood cell counts. Receiver operating characteristic (ROC) curves demonstrated that serum hsa_circ_0079480 levels were able to effectively differentiate between patients with AML and healthy controls. Moreover, the upregulation of serum hsa_circ_0079480 was found to be closely related to clinicopathological findings and to be an independent predictor of reduced overall and relapse‐free survival among individuals diagnosed with AML. Furthermore, serum hsa_circ_0079480 levels were markedly decreased after treatment in this patient population, with these levels being lower in patients that achieved complete remission as compared to those patients that did not. Conclusion Levels of hsa_circ_0079480 in patient serum may offer value as a prognostic biomarker in AML.

show abstract

“…Though treatment of this disease has made huge progress over the past years, the 5‐year overall survival rate of AML patients remains unfavorable, ranging from 11%‐55% 4,5 . Therefore, identifying novel and reliable prognostic biomarkers for risk stratification of AML patients is critical for selecting the optimal therapeutic strategies and improving the clinical outcome 6,7 …”

Section: Introductionmentioning

confidence: 99%

“…4,5 Therefore, identifying novel and reliable prognostic biomarkers for risk stratification of AML patients is critical for selecting the optimal therapeutic strategies and improving the clinical outcome. 6,7 MicroRNAs (miRNAs) are small (19-25 nucleotide), noncoding…”

Section: Introductionmentioning

confidence: 99%

Serum miR‐22 is a novel prognostic marker for acute myeloid leukemia

Zheng

Cheng

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background It has been demonstrated that aberrant expression of serum microRNAs is potential markers for the prognostic prediction of acute myeloid leukemia (AML). However, the clinical significance of serum miR‐22 remained uncovered. In this study, we aimed to explore the potential prognostic value of serum miR‐22 for AML. Methods Blood samples were collected from 124 patients with AML and 60 healthy individuals. Serum miR‐22 level was detected by quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR), and its potential clinical value was investigated. Results Our results showed that serum miR‐22 expression was significantly downregulated in AML subjects compared to healthy controls. Serum miR‐22 levels were lowest in AML patients with M4/M5 subtypes, and low serum miR‐22 expression occurred more frequently in AML patients with higher white blood cell counts or poor cytogenetic risk. Receiver operating characteristic (ROC) analysis revealed that serum miR‐22 well differentiated AML cases from healthy controls. In addition, serum miR‐22 downregulation was closely associated with worse clinical features and shorter survival. Low serum miR‐22 expression was confirmed to be an independent predictor for overall survival and relapse‐free survival in AML patients. Moreover, the expression level of serum miR‐22 was dramatically increased following treatment. In addition, serum miR‐22 levels were significantly higher in AML patients achieving complete remission (CR) than those without CR. Conclusion Collectively, serum miR‐22 might serve as a novel and promising prognostic biomarker for AML.

show abstract

Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients

Cited by 8 publications

References 17 publications

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia

Serum hsa_circ_0079480 is a novel prognostic marker for acute myeloid leukemia

Serum miR‐22 is a novel prognostic marker for acute myeloid leukemia

Contact Info

Product

Resources

About